Floatz logo

Yttrium-90 Conjugated Chimeric G250

Kidney Neoplasm

Ludwig Institute for Cancer ResearchradiopharmaceuticalPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

42 Active assets in the Kidney Neoplasm cohort.

Asset / SponsorPhaseRating
Nivolumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BBB
Bms-907351
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pembrolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Ipilimumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Arestin
RenJi Hospital
Phase 3B

View all 50 →

Same molecule, other indications

Yttrium-90 Conjugated Chimeric G250 is also rated in:

kidney cancerDormant
CC
Indicative ·
42 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →